South Dakota 2022 Regular Session

South Dakota House Bill HB1292

Introduced
2/2/22  
Refer
2/4/22  
Report Pass
2/15/22  
Engrossed
2/17/22  
Refer
2/22/22  
Report Pass
2/25/22  
Enrolled
2/28/22  

Caption

Regulate delta-8 tetrahydrocannabinol, THC-O acetate, and hexahydrocannabinol for those under the age of twenty-one.

Impact

If enacted, HB1292 would change state laws surrounding the regulation of cannabis products by creating age restrictions targeted at protecting young people from the health implications of consuming these substances. This legislative action is part of a broader trend towards regulating cannabis-derived products in response to growing public interest and the need for consumer protection. This bill represents a step in establishing legal frameworks that govern not only sales but also possession among underage individuals, similar to alcohol and tobacco regulations.

Summary

House Bill 1292 aims to regulate certain cannabinoids, specifically delta-8 tetrahydrocannabinol, THC-O acetate, and hexahydrocannabinol, by prohibiting their sale to individuals under the age of twenty-one. The bill establishes clear legal parameters around these substances and creates penalties for violations, thereby seeking to protect minors from potential health risks associated with their use. Specifically, the measure makes it unlawful for sellers to knowingly distribute these products to minors, as well as prohibiting the acquisition and possession of these substances by individuals under the specified age. Violations are designated as a Class 2 misdemeanor.

Sentiment

The sentiment surrounding HB1292 appears to be generally positive among lawmakers focused on public health and youth protection. Supporters argue that the regulation of these cannabis products is necessary to ensure that young, vulnerable populations are shielded from potential harm associated with their use. However, discussions could also reflect concern about the effectiveness and enforceability of such regulations, particularly given the complexities involved in monitoring compliance and defining the products in question.

Contention

Notable points of contention may arise regarding the enforcement of the age restrictions stipulated in HB1292, with potential challenges posed by the burgeoning cannabis market, including concerns over illegal sales or the loopholes in legislation. Critics might raise questions about whether the penalties are sufficient to deter violations or if further measures are needed to ensure that these products do not end up in the hands of minors. Additionally, the overall impact of restricting access to these substances on public health could lead to broader discussions about the balance between regulation and personal freedoms.

Companion Bills

No companion bills found.

Previously Filed As

SD HB1078

Cannabis - Regulation - Delta-8- and Delta-10-Tetrahydrocannabinol

SD SB788

Cannabis - Regulation - Delta-8- and Delta-10-Tetrahydrocannabinol

SD HB1236

Regulate tetrahydrocannabinol for medical use.

SD SB358

To Prohibit Industrial Hemp That Contain Certain Delta Tetrahydrocannabinol Substances; To Include Certain Tetrahydrocannabinol In The List Of Schedule Vi Controlled Substances; And To Declare An Emergency.

SD SB605

To Create The Delta Tetrahydrocannabinol Excise Tax Act; And To Tax Delta Tetrahydrocannabinol Products.

SD SB2096

Definitions, prohibited acts by licensees, schedule I controlled substances tetrahydrocannabinols, and bonding requirements for grain buyers; and to provide a penalty.

SD A5440

Prohibits production and sale of products containing delta-8 tetrahydrocannabinol.

SD S3944

Prohibits production and sale of products containing delta-8 tetrahydrocannabinol.

SD SB205

Intoxicating Hemp And Tetrahydrocannabinol Products

SD HB1226

Regulate industrial hemp-derived delta-8 and delta-10 tetrahydrocannabinol products, and other hemp-derived psychoactive compounds, and to declare an emergency.

Similar Bills

No similar bills found.